The expression of p16 in the present study differedbetween the controls and patients; it occurred during boththe G0/G1 and S phases in the control group, but duringall 3 phases in the CML group, and its level of expression in the CML group during the S phase was significantlyhigher than that in the control group (P < 0.05). The gene discussed is CDKN2A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.